• The number of bladder cancer cases in 2020 is estimated at 81,400, nearly 4.5% of all newly diagnosed cancer cases, and the current bladder cancer research market is projected to grow at a CAGR of 4.03% through 2026
• White light, the most widely accepted current standard of care for bladder cancer removal, may not be the best option in helping to prevent recurrence, leaving hundreds of thousands of patients afraid of relapse
• Blue light has been introduced and proven to detect 25% more tumors, but because of limitations, has not been widely accepted
• Imagin Medical’s i/Blue Imaging System(TM) can be used alongside the current surgical endoscopic tools for a side-by-side comparison of both white and blue-light imaging in real time

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is focused on establishing new standards of care in the visualization of cancer during minimally invasive procedures. With an initial focus on bladder cancer, the company aims to address the limitations surgeons face during cystoscopies. The current standard of visualizing bladder cancer during surgery is white light illumination, a procedure that has been used for more than three decades and commands 90 percent of the market.

White-light illumination is effective when it comes to visualizing cancerous tumors protruding above the bladder wall, but flat tumors can look the same as normal tissue and are almost impossible to visualize with white light.

These limitations are successfully overcome with the use of blue light. The problem, however, is that blue light cannot be used during removal of the cancer. Surgeons are therefore required to switch back and forth between white light and blue light during surgeries, losing the real-time observation comparison advantage.

Imagin Medical’s proprietary i/Blue Imaging System(TM) addresses the limitations surgeons face in this regard by simultaneously displaying both white-light and blue-light images side by side, in real time.

Using an FDA-approved imaging agent, the i/Blue System is unlike other systems available on the market today in that it can attach to almost any endoscope model that is currently on the market. Due to this compatibility, any hospital adopting the i/Blue Imaging System will be able to do so in a cost-effective manner without needing to replace their current surgical instruments.

The technology has the potential to revolutionize the current standard of care for bladder cancer patients and help position Imagin Medical as a leading provider of effective solutions in the vast market of bladder cancer research and therapeutics. Bladder cancer is the sixth most prevalent form of cancer and the most expensive one to treat in the United States. The number of new bladder cancer cases in the next year is estimated to reach 81,400, or 4.5% of all newly diagnosed cancer cases, while the estimated number of deaths from bladder cancer in likely to reach 17,980, or 3% of all cancer-related deaths (https://ibn.fm/bjiHj).

According to Verified Market Research, the global bladder cancer research market reached $3.43 billion in 2018. Through 2026, the market is expected to grow at a CAGR of 4.03%, resulting in a projected $4.71 billion in total market growth (https://ibn.fm/HkgN1).

Of all the forms of cancer, bladder cancer has one of the highest recurrence rates among all cancer forms. This leaves an estimated 600,000 people living in fear that their cancer will return, according to Imagin Medical. The company is committed to addressing these fears and making the i/Blue System more broadly accessible for the removal of cancer, potentially lowering recurrence rates.

Imagin Medical announced in late November that it had closed the first $750,000 tranche of a proposed offering of up to $3 million of convertible notes. All securities that have been issued in connection with this offering will be subject to the statutory hold period of four months plus a day from the date of issuance (https://ibn.fm/yzjHS).

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• PacRoots Cannabis updated investors following first successful hemp harvest derived from joint venture with Rock Creek Farms
• Initial harvest yielded 105,000 lbs of biomass of exceptional quality; yield was sold in its entirety to Speakeasy Cannabis Club
• Harvest was particularly remarkable given that it was produced despite region’s poor prevailing weather conditions
• Global CBD oil, consumer health market poised to grow to value of $123.2 billion by 2027

PacRoots Cannabis (CSE: PACR) (OTCQB: PACRF), a Canada-based cannabis company dedicated towards producing premium-quality strains and products by leveraging a genetics-focused approach, has recently updated its investors and stakeholders following the company’s first successful hemp harvest on its 100-acre site situated in British Columbia’s South Okanagan Valley (https://ibn.fm/0lGHr). Following the award for an industrial hemp license by Health Canada on May 22, 2020, which permitted Pac Roots Cannabis Corp. to cultivate, sell, possess and process industrial hemp, the Company entered into a binding letter of intent with Rock Creek Farms to form a joint venture with the intent to plant hemp CBD seedlings on 100-acres of prime arable land in British Columbia (https://ibn.fm/7dMzT). Planting commenced in mid-June 2020, with approximately 130,000 premium hemp CBD plants placed systematically throughout the two 50-acre parcels comprising the site. PacRoots revealed that its initial harvest had been a remarkable success, yielding a quality which was far higher than expected; the Company also announced that the entire biomass yield of over 105 thousand pounds is being processed and sold to Speakeasy Cannabis Club (CSE: EASY).  Furthermore, PacRoots elaborated on its low-cost production capabilities, which the Company believes provides it with a decisive and sustainable competitive advantage while continuing to maintain healthy profit margins. “We are very proud of our team and partners at Rock Creek Farms who have been committed to the vision and dedicated to achieving success […] PacRoots and our partners are thrilled to build on this success as we launch into 2021 with various exciting projects,” said PacRoots Cannabis President and CEO Patrick Elliott in reference to the harvest. The Company also highlighted the remarkable nature of the harvest, given that it had come amid less-than-ideal meteorological conditions. British Columbia’s spring season in 2020 was decidedly atypical, with a wet spring and a cold harvest, while the fall ended earlier than usual with freezing temperatures and snow.  PacRoots and Rock Creek Farms were able to limit the frost exposure and damage to their hemp crop through a series of measures, including staggered planting and harvest, system controls, several varieties of genetics and a strong personnel crew, all of which in combination enabled the joint venture to recover far more biomass than would have been expected. “2020 has thrown many things at us, the latest was snow and freezing weather that broke all records in the area dating back to 1886 when they began keeping records in Rock Creek,” remarked the joint venture’s operation advisor Marc Green. “We feel fortunate to have recovered most of the biomass from the 100-acres while most of our peer group failed to recover any significant yield.” Going forward into 2021, the PacRoots Cannabis – Rock Creek Farms joint venture anticipates a strong planting season, seeking to build upon the lessons learned over the prior season. With the global CBD oil and CBD consumer health market set to grow to a market value of $123.2 billion by 2027 (https://ibn.fm/ubKCP). PacRoots Cannabis Corp. seems well poised to benefit from the explosive growth in demand for their product. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• Ease of use, compatibility with third-party EEG amplifiers has created diverse target markets for BRSF’s NeuroCap
• Recent forecasts show telemedicine industry expected to experience CAGR of 15.1% through 2027
• BRSF has potential to disrupt sleep industry, which is forecast to reach $585 billion by 2025

Brain Scientific (OTCQB: BRSF) is offering solutions to the EEG industry’s limitations. The current method of administering an EEG is slow and expensive, plus requires specialized EEG technologists and bulky equipment. This essential procedure is not easily accessible to all, particularly those in rural communities, because of the expense and a neurologist shortage.

The NeuroCap(TM) is Brain Scientific’s patented, disposable EEG headset. FDA cleared, the revolutionary device can be set up by any clinical personnel within five minutes. The headset is third-party compatible and has no bulky equipment. The NeuroCap makes EEGs accessible to anyone who needs one.

The ease of use and compatibility with third-party EEG amplifiers has created a diverse target market for NeuroCap. Typically EEGs are administered primarily at hospitals or neurology practices, but the NeuroCap makes EEGs available to other markets not previously seen as viable options.  Two growing industries that Brain Scientific plans to target as potential markets are telemedicine and sleep studies.

Last year — 2020 — saw a significant increase in telemedicine. The CDC reported that the first quarter of 2020 saw an increase of 50% from the previous year while week 13 experienced a 154% increase (https://ibn.fm/hA0Rc).

Dr. John Hixson, an associate professor of neurology at the University of California San Francisco and the San Francisco VA, described the NeuroCap as an attractive device in situations where there is no standard of care currently. “In community hospitals, they typically don’t have EEG resources,” noted Hixon, “Yet the question of whether a person is having a subclinical seizure or not comes up quite frequently” (https://ibn.fm/BwArg).

Nurses at these facilities would be able to apply the headset, collect the EEG signals quickly and then access a neurologist remotely, Hixon explained.

Changes in the CPT Code, or numbers used to identify medical services and procedures furnished by qualified healthcare professionals, show a significant change in outpatient codes, the first large overhaul in more than 25 years (https://ibn.fm/YMfPW). This change reflects the changes within the industry as the demand for telehealth continues to increase.

In 2019, the telemedicine market size was estimated at $41.4 billion globally, and recent forecasts show the industry is expected to experience a compounded annual growth of 15.1% through 2027. Part of this increase is credited to the need for improved care while also reducing the burden on medical professionals (https://ibn.fm/q2Jwp).

Telemedicine is not the only sector in need of portable, low-cost, reliable equipment. The sleep industry is seeing an uptick in clients as 50 to 70 million people in the United States suffer from one or several sleep disorders. With more than 4,700 sleep centers and labs across the country, these potential patients can access the care they need (https://ibn.fm/3G0a0). Many of them will need an EEG as abnormalities in sleep may be a sign of neurologic disorders (https://ibn.fm/56K5T).

There is a move within the sleep clinics to provide at-home sleep studies due to the convenience and lower cost. However, at-home studies only monitor breathing. The addition of the NeuroCap to a sleep clinic’s toolbox will provide higher convenience. With the sleep industry worldwide expected to reach $585 billion by 2025 (https://ibn.fm/JEL1m), this is a lucrative market BRSF has the potential to disrupt.

Brain Scientific is creating innovative ways to make a much-needed medical procedure more accessible to all.

For more information, visit the company’s website at www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Following the success of the Venue Bubble and Travel Bubble projects, Loop has partnered with Draganfly Inc. to launch the first Film Bubble for a major motion picture in January 2021
• The film and television industry has seen a significant drop in revenue, and the Film Bubble is positioned to make sets safer with the technology provided by Draganfly
• Effective December 11, 2020, Mark Lotz took over the position of Chief Financial Officer after the resignation of Abbey Abdiye

Loop Insights (TSX.V: MTRX) (OTCQB: RACMF), an innovative Internet of Things (“IoT”) technology company that delivers contactless solutions, including venue management, personalized engagement, and AI-driven insights, is partnering with Draganfly Inc. (CSE: DFLY) (OTCQB: DFLYF) (FSE: 3U8)) to launch the first “Film Bubble,” a solution designed to help keep movie sets safer and operational during the coronavirus pandemic (https://ibn.fm/tJAKt). The Film Bubble provides another major opportunity for Loop as a spin-off of the recently successful NCAA Venue Bubble and Travel Bubble projects. According to Loop CEO Rob Anson, the Film Bubble will provide a great showcase for the company’s film industry solution as well as additional opportunities for travel, venue, and other healthcare applications Loop Insights has been working on. The Film Bubble will be launched for a major motion picture scheduled to commence filming in January 2021. At this time, the names of the motion picture and the actors are being kept confidential until filming begins. Under the partnership agreement, Loop Insights and Draganfly will combine technologies into Loop’s Venue Bubble solution with the ultimate goal of making the film and television industry safer to resume production, resulting in higher revenue and employment opportunities. “Film industry investors, insurance companies, unions, and guilds are all seeking this type of solution to keep workers safe and protect their investments,” Draganfly CEO Cameron Chell said. Draganfly provides Safe Set Solutions for the global film and television production industry using ground-based technology for symptom pre-screening, elevated body temperature measurement, and social distancing display. The Film Bubble solution comes at the right time for an industry that has reported billions in losses as a result of the coronavirus pandemic closing down movie theaters and production. In 2019, the North American box office amounted to $11.32 billion in total earnings and employed over 456 thousand people with several hundred thousand more employees in Canada and other countries worldwide (https://ibn.fm/hVmFz). This past November, AMC Theatres announced that they had seen a 91% drop in their revenues during the most recent earnings period resulting in a loss of $906 million in this quarter alone. The overall global entertainment industry is also projected to lose $160 billion of growth over the next five years (https://ibn.fm/Kr0Wj). “The addition of Draganfly’s Safe Set Solutions to our Venue Bubble Platform creates an instant and powerful Film Bubble solution for an industry that has suffered catastrophic losses in 2020 and can’t afford to stay shut down for a minute longer,” Anson said. “We are extremely proud to have jointly delivered a solution to the film industry that will allow them to safely get their crews, actors, and supporting infrastructure back to work and generating prosperity, the ripple effects of which reverberate around the world.” On the same day the Film Bubble partnership was made public, Loop Insights announced the appointment of a new Chief Financial Officer. The previous CFO, Abbey Abdiye, resigned from the company to pursue other career opportunities. He is replaced by Mark Lotz, who took over the position effective December 11, 2020 (https://ibn.fm/Vicrd). Lotz is a Chartered Professional Accountant with 26 years of post-qualification experience. His experience spans across a broad cross-section of industries that include SaaS, mining, manufacturing, financial service, and technology. Lotz has a Bachelor’s degree in Business Administration with a dual Economics major. Backed by Amazon’s Partner Network, Loop has developed a line of powerful technologies that are simple to use but designed to transform industries. Fobi, an IoT device that is designed to seamlessly integrate with any existing point of sale infrastructure, collects 100% of the transactional data and sends it to the cloud. SmarTap is Loop’s Near Field Communication (“NFC”) device that enables consumers to check-in using a “tap” and their smartphone’s NFC compatibility. SmarTap offers a contactless consumer experience and connects with the cloud via LTE or WiFi to securely transmit data. Loop Cloud is the middle ground where Fobi and SmarTap’s information meets, being stored digitally and creating a database for the company and their clients. When paired with either Loop solution, the Loop Cloud creates a way for the business to transform their edge-based legacy systems into a unified database. For more information, visit the company’s website at www.LoopInsights.ai. NOTE TO INVESTORS: The latest news and updates relating to RACMF are available in the company’s newsroom at https://ibn.fm/RACMF

• MAZAKALI’s management team has vast experience in the cannabis industry, helping uniquely position the company to dominate one of the fastest-growing industries in the world
• The MAZAKALI management team has extensive experience at Fortune 500 companies, including UBS, JP Morgan, Merrill Lynch, Apple, AliBaba and AT Kearney
• The cannabis market is expected to reach $73.6 billion by 2027, growing at a CAGR of 27%
• The company places authority and knowledge on the same pedestal, providing GreenPapers(R) as a valuable educational tool for the public on all topics and trends related to the high-growth cannabis industry; over 70 GreenPapers(R) have been published since 2016, attracting over 70,000 subscribers to date
• The MAZAKALI investment team is comprised of licensed investment bankers and Registered Investment Advisors; securities are offered via a registered broker/dealer
• MAZAKALI’s online marketplace serves cannabis capital formation with scalability, sustainability and sensibility
• MAZAKALI aims to create a healthier and sustainable world through the purposeful placement of capital

A cannabis-focused fintech marketplace based in San Francisco, MAZAKALI offers investment opportunities in the high growth cannabis industry. Supported by a broker/dealer and acting as a Registered Investment Adviser, the company has been supporting cannabis businesses in raising capital since 2016. MAZAKALI was founded to counteract the negative consequences of business practices by making investments in sustainable cannabis. By shepherding capital in a responsible and ethical manner, MAZAKALI and its clients envision a world where capital investment will play a significant role Beyond Impact. The company’s financial services leverage deep relationships, rigorous analytics and reliable research focused on uncovering investment opportunities in the high growth cannabis sector. The company features a deep bench of educated, experienced and licensed professionals to support clients with their capital and investment needs. Investor Services

• Online Investment Marketplace:Investors gain access to a pipeline of vetted investment opportunities; diversified across sectors and geography. In addition to direct investments, MAZAKALI offers managed funds and custom portfolios.
• Custom Portfolios:Investors seeking to place capital in excess of $1MM can take advantage of separately managed accounts designed and managed by licensed investment advisors. Custom portfolios offer several advantages over collective funds, including personalization, reduced expenses and tax benefits.
• Institutional Investor Services:MAZAKALI introduced the first Outsourced Cannabis Investment Officer (“OCIO”) service in 2019, providing its portfolio management expertise to those institutions with capital and interest seeking knowledge and access.

Issuer Services Every successful capital raise begins with proper preparation. Since its inception, MAZAKALI has specialized in supporting cannabis-related businesses by helping them prepare to raise capital. Cannabis firms that collaborate with MAZAKALI gain access to insight acquired through the hands-on experience of MAZAKALI’s management team. By providing comprehensive services throughout the entire fundraising process, MAZAKALI helps businesses save time and show well to potential investors at every stage. The company’s services include:

• Preparation stage:Initial consultation, business review, structural analysis, strategic planning, expansion agenda
• Structure offering stage:Capital advisory, capital cadence, deal structure, financial instrument selection, initial raise terms
• Modeling stage:Pro Forma financials, income statement, balance sheet, cash flow statement, assumption review, business valuation
• Pitch preparation stage:Pitch deck, investment deck, pitch practice, Q&A practice, pitch video
• Offer launch stage:Digital platform listing, pitch video, term sheet, Pro Forma model, financials, cap table, subscription docs, automated workflow, offer marketing

Education – GreenPapers(R) The company believes in ‘Authority Through Knowledge’. To help educate the public about the cannabis markets, MAZAKALI uses GreenPapers(R) to share deep trends and insights that matter to investors and operators alike. GreenPapers(R) archives span from 2016 to the present, with the most recent insight report focusing on major cannabis trends in 2021. Titled Cannabis 2021: Five Things to Watch, the report underlines that 2021 is poised to be a pivotal year for the cannabis sector amid growing political support, legalization in 70 percent of U.S. states, increased public focus and local governmental interest in gaining tax revenue from the market (https://ibn.fm/sAT1z). All of these factors and more are likely to make cannabis the best performing asset class of the decade, the report forecasts. The report also lists the five major trends expected in 2021:

• Rise of the cannabis beverage
• Biosynthesis
• Accelerated state and local market adoption
• Expanded capital participation
• Global growth

Technology MAZAKALI’s online marketplace was designed to provide compliance, convenience and confidence to the cannabis private equity investment process. The company’s investment services include education, research and execution on an intuitive digital interface. Investors can gain exposure to direct placements, managed accounts and third-party funds in a compliant and convenient marketplace. Market Outlook The global growth forecast by MAZAKALI is backed by other analysts and experts in the niche. According to Grand View Research, the global cannabis market is expected to grow exponentially amid increased acceptance of the plant worldwide. The industry is anticipated to reach $73.6 billion by 2027, expanding at a CAGR of 18.1%. In 2019, the largest revenue shares for cannabis belonged to North America, resulting in 88.4% of the worldwide market (https://ibn.fm/vmq3Z). According to a BCC Research report, the plant-based and botanical-derived drug market is also expected to grow globally and reach an estimated $39.6 billion valuation by 2022, marking a CAGR of 6.1% from the 2017 market value of $29.4 billion (https://ibn.fm/3f717). Management Team Sumit Mehta is the Founder and CEO of MAZAKALI. A cannabis strategist, Mr. Mehta is an internationally recognized speaker and the author of the MAZAKALI GreenPaper(R). In addition to his role leading MAZAKALI, Mr. Mehta serves on several cannabis company boards and is the Chair of the Banking and Financial Services committee for the National Cannabis Industry Association. Mr. Mehta is the former Director of Finance for the Arcview Group and, prior to entering the cannabis industry full-time in 2016, spent 20 years on Wall Street at firms including JP Morgan, UBS and Merrill Lynch. Mr. Mehta has earned an MBA from the Ross School of Business at the University of Michigan and a BA with Honors in Economics with minors in Math and Physics from the University of Texas at Austin. Mr. Mehta holds FINRA 7, 63, 65 and 79 licenses, as well as a Certificate in Financial Technology from Harvard University. Craig Piatti is the company’s Chief Operating Officer. He is responsible for developing and driving the firm’s infrastructure, technology and organizational processes. Prior to joining MAZAKALI, Mr. Piatti worked at Alibaba’s cloud computing division on strategic business development. He has also worked with global firms including SAP, Bosch and China Telecom. He holds an MBA from the University of Notre Dame – Mendoza College of Business and a BS from Indiana University – Kelly School of Business. He also holds a Diplom-Betriebswirt (“BWL”) from Reutlingen University in Germany and a FINRA 65 license. Mary Beth Barron is MAZAKALI’s Chief Marketing Officer. Ms. Barron leads the company’s marketing strategy, brand management, communications, advertising, public relations and digital marketing. Bringing more than 20 years of marketing and business leadership experience, her career started at Apple Far East (Hong Kong). She served as a top marketing leader for several global professional services – giving her marketing responsibilities in more than 30 countries. Ms. Barron holds an MBA from the Kellogg School of Management at Northwestern University and a BA from The Colorado College. Bob Peatman is the Director of Investments for MAZAKALI. Mr. Peatman is responsible for assisting wealth managers and investors with cannabis-related investment opportunities. Mr. Peatman has worked with retail and institutional investors throughout his financial career, with a focus on digitizing and expanding national sales distribution networks. He holds an MBA from Babson College and a BA from St. Lawrence University. Justin Schleifer is MAZAKALI’s Director of Compliance. Mr. Schleifer is responsible for developing the firm’s controls and overseeing its advisory business. He is also the CEO and Co-Founder of Aspect Advisors, a San Francisco-based compliance consulting firm for asset managers, broker-dealers and fintech businesses. Schleifer has extensive experience interfacing with the SEC, FINRA and the NFA. He earned his BS in Hotel Administration, concentrating in Business Law, from Cornell University. He also holds FINRA Series 7, 24, 27, 55, 66, 79 and 87 licenses. Mathew Auric serves as Legal Counsel for MAZAKALI. In his role, Mr. Auric is responsible for general legal support, including contract drafting and negotiation, internal business structuring, strategic planning and liability management. Mr. Auric is a corporate attorney with cannabusiness firm Hoban Law Group, with a deep understanding of the regulatory, practical and historical issues involving cannabis. He received his JD from Ventura College of Law and a bachelor’s degree from the University of California, Santa Cruz. For more information, visit the company’s website at www.MAZAKALI.com. NOTE TO INVESTORS: The latest news and updates relating to MAZAKALI are available in the company’s newsroom at https://ibn.fm/MAZAKALI

• Josemaria Resources developing its wholly owned flagship Josemaria Copper-Gold Project
• VanEck report details investment value of ‘junior’ mining companies
• Global smart mining market estimated to reach $6.8 billion last year, forecast to reach $20.31 billion by 2025

For investors looking for high-growth potential, junior mining companies may fit the bill, according to a recent report released by VanEck, an investment management company (https://ibn.fm/Cvv8W). That’s good news for Josemaria Resources (TSX: JOSE) (OTCQB: JOSMF), a natural resources company that is offering an advanced-stage copper-gold deposit project located in Argentina, a rare find in a junior mining company.

The VanEck report, titled “The Investment Case for Junior Gold Miners,” notes that “a dynamic and important subset of the global gold-mining industry is a group of companies known as ‘juniors.’ These are small- to medium-size market capitalization companies that are generally actively engaged in the development of new sources of gold either through greenfield exploration or the use of new geologic models to prospect for gold in overlooked or abandoned properties. For investors, juniors may offer characteristics similar to an investment in venture capital—early stage, high risk, but with a potential for high growth.”

Josemaria is looking for that type of high-growth return as it eyes key growth in a global smart mining market that was estimated to reach $6.8 billion last year and forecast to reach $20.31 billion by 2025 (https://ibn.fm/6Cc28). The company is focusing on the development of its wholly owned flagship Josemaria Copper-Gold Project located in the San Juan Province of Argentina. San Juan is a well-known mining hub supporting a wide variety of mining companies, where the Lundin Group, the parent company of JOSE, has been active for almost 30 years.

JOSE recently released the results of a feasibility study for its Josemaria Copper-Gold Project. The study reports a robust, rapid pay-back, low-risk project, with an open-pit operation feeding a conventional process plant at an average of 152,000 tonnes per day. The study also projected a mine life stretching more than 19 years and yielding average annual metal production of 136,000 tonnes of copper, 231,000 ounces of gold and 1,164,000 ounces of silver.

“We are extremely pleased with the results of the Feasibility Study at Josemaria, which indicates that this is one of the very few readily developable copper-gold projects in the world today,” said Josemaria president and CEO Adam Lundin. “This study has materially de-risked the project and forecasts an attractive economic outcome which is comparable with other large-scale copper/gold projects already being developed or in production today.”

Josemaria Resources is a Canadian natural resources company based in Vancouver, British Columbia. The company’s current focus is on advancing the development of its wholly owned Josemaria copper-gold mining project. Josemaria Resources is part of the Lundin Group of companies, a conglomerate of 13 business entities operating in the mining, oil and gas and renewables sectors around the world.

For more information on Josemaria Resources, visit the company’s website at www.JoseMariaResources.com.

NOTE TO INVESTORS: The latest news and updates relating to JOSMF are available in the company’s newsroom at https://ibn.fm/JOSMF

• Company extends expiration of special dividend for one year
• If declared, special dividend will consist of number, designation determined by company management
• BIGtoken is first consumer-managed data marketplace where people can own, earn from their data

SRAX (NASDAQ: SRAX) will extend the expiration for its previously announced BIGtoken special dividend right for one year. The dividend right was set to expire on or before 5 p.m. on Dec. 31, 2020, and that deadline has been extended to on or before 5 p.m. ET on Dec. 31, 2021 (https://ibn.fm/sCKWJ). The original dividend right was issued on Sept. 17, 2018, when SRAX, then called Social Reality Inc., announced a nontransferable right to receive at no charge a special dividend to holders of the company’s Class A common stock; the right was also extended to certain holders of the company’s common stock equivalents. The extension announcement notes that “if and when declared, the Special Dividend will consist of such number and designation of the SRAX subsidiary BIGtoken Inc.’s securities as determined by the company’s management at their sole discretion. . . . The Special Dividend will be an analog security, i.e., not digital, and not a cryptocurrency, and the Special Dividend is expected to be a fractional non-voting security that, if and when issued, is expected to only participate in a portion of the financial performance of the BIGtoken platform.” Initially launched by SRAX and then spun off as a separate company, BIGtoken, or BIG, is a secure consumer data-management and distribution system —the first consumer-managed data marketplace where people can own and earn from their data (https://ibn.fm/nr4Sm). Through a transparent platform and consumer reward systems, BIG offers consumers choice, transparency, and compensation for their data. Participants earn rewards, and developers are able to build pro-consumer online experiences on top of the BIG platform (https://ibn.fm/gXpcG). At last count, BIGtoken has compensated more than 16 million users for access to their data while creating data sets across 25,000 unique market segments. Brands are offered access to this verified, opted-in data for a fee. “BIGtoken is a secure platform that empowers you to realize and claim the value of your digital self,” the website observes (https://ibn.fm/B0Cj3). “You have a right to privacy, awareness, and choice when it comes to the data you put out into the digital world. With BIG, you can own and earn from that data while staying connected to your community.” SRAX is currently focused on unlocking data and insights through its software-as-a-service (SaaS) platform, Sequire. Launched as a standalone platform in early 2020, Sequire now has more than 1 million investors and traders, with an estimated 91 publicly listed companies as subscribers. The explosion in growth is driven by Sequire’s extensive range of services and as companies have increasingly sought to adopt digital technology and the data generated from such mediums as a way of improving their engagement with customers and stakeholders alike. For more information about SRAX and Sequire, visit the companies’ websites at www.SRAX.com and www.MySequire.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• IND approval from the FDA has given CNS Pharmaceuticals the green light needed to continue with clinical research of Berubicin in patients suffering from GBM and other brain/nervous system cancers
• Company holds the exclusive worldwide license for Berubicin, the first anthracycline to cross the blood-brain barrier in the adult brain
• The GBM therapeutics market is expected to increase to an estimated $3.3 billion in 2024
• CNS Pharmaceuticals’ sublicensee will be conducting the first pediatric study using Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is a clinical-stage biotechnology company that is currently specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, including the use of Berubicin for patients with glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. CNS is currently working on the development and clinical trials of Berubicin for GBM and the potential of addressing other central nervous system malignancies.

Berubicin appears to be the first anthracycline to cross the blood-brain barrier in the adult brain. Its development started over 15 years ago when Reata Pharmaceuticals, Inc. (NASDAQ: RETA) conducted the first Phase I trial, creating limited clinical data. Phase I trial results indicated that 44 percent of participants reported a significant improvement in the size of the tumor. The evidence concluded that there was a positive enough impact that CNS has continued with the development and the clinical-stage trials for the drug.

CNS holds the exclusive license for Berubicin worldwide. The company goes into the year 2021 determined to move forward with the development and distribution of Berubicin for GBM. The recent approval of the United States Food and Drug Administration (“FDA”) of Berubicin as an investigational new drug (“IND”) has only increased the opportunity for CNS to move forward with the three clinical trials currently in development.

“The company will transform within the next several months as Berubicin becomes the subject of up to three active clinical trials, which include our randomized, controlled Phase II trial in the U.S., and two trials planned by our sublicensee WPD in Poland,” CNS Pharmaceuticals CEO John Climaco said during a recent virtual presentation discussing the FDA IND approval and future company plans (https://ibn.fm/TP3oE).

The company’s sublicensee WPD Pharmaceuticals (CSE: WBIO) (FSE: 8SV1) will be conducting a Phase II trial in adults, as well as the first-ever Phase I trial in children who suffer from GBM and other cancers of the brain and central nervous system. This is the first pediatric trial of its kind.

According to Climaco, CNS aims to address the significant unmet medical need of GBM patients since the current treatment paradigm for the condition yields bleak results, and this aggressive and, as yet, incurable form of brain cancer continues to claim high mortality rates. “We have a tremendous opportunity ahead of us as we continue our mission to improve patient outcomes for GBM and build on the promising results demonstrated by Berubicin in its Phase 1 clinical trial,” he added.

The GBM treatments market is anticipated to increase to an estimated $3.3 billion in 2014, marking a CAGR of 17.4% from 2014, when the market was $659. The growth is expected to be driven by seven major markets – the United States, Spain, the UK, France, Italy, Japan, and Germany, and is the direct result of the growing unmet needs of the current market (https://ibn.fm/ZAYjM).

Berubicin is currently being produced in two labs as a result of a dual-track manufacturing strategy implemented by CNS. To ensure that current conditions do not hinder the progress of Berubicin’s development and availability, CNS has turned to United States-based Pharmaceuticals International Inc. and Italy-based BSP Pharmaceuticals SpA for the production of Berubicin for the clinical trials. Both pharmaceutical companies have diversified the supply chain, and increased the availability of Berubicin, mitigating the risks of COVID-19 in clinical trial strategies.

For more information, visit the company’s website at www.CNSPharma.com

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Surgical imaging company Imagin Medical Inc. has developed a proprietary technology that enhances surgeons’ efforts to identify the full extent of bladder cancers and remove them
• Imagin’s i/Blue Imaging (TM) System uses blue light in combination with a fluorescent contrasting agent that highlights the tumor on an endoscope’s camera display to help surgeons remove the cancerous cells more completely than the white light standard
• Bladder cancer is the fourth most common cancer in men and the second most common genitourinary cancer
• The American Cancer Society forecasts that, during this year, about 81,400 new cases of bladder cancer would be reported and that about 17,980 people would die from the disease
• While Imagin’s initial focus is on making its technology effective and available for fighting bladder cancer, the company intends to expand its platform to work with other minimally invasive surgical procedures such as thoracic and laparoscopic

The rich blue of a daytime sky and the darker hues of a deep pool of water can evoke images of serenity for the troubled mind, while high-energy blue light at the darker end of the visible light spectrum serves health-enhancing functions such as boosting individuals’ alertness, helping memory and cognitive function, and elevating mood. It also helps to regulate the body’s natural wakefulness and sleep cycle known as the circadian rhythm (https://ibn.fm/kvAYr).

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is harnessing the virtues of blue light in an additional, health-enhancing way. By utilizing the company’s proprietary i/Blue Imaging (TM) System with a contrast agent, surgeons will be able to better visualize the parameters of cancers and then develop the appropriate response strategy.

Imagin’s platform is being developed for use in bladder cancer surgery. It relies on the drug, Cysview, which rapidly infiltrates the cancer cells and causes them to glow bright pink under blue light. The drug is administered just before surgery and the blue light is used endoscopically to locate and examine the tumor.

Endoscopic and laparoscopic imaging technology have revolutionized surgical medicine with their minimally invasive advanced optics and light sensors. Cameras and recording devices attached to long, thin tubes inserted into the body through the digestive tract or a small incision elsewhere have eliminated the need for many open surgical procedures — reducing patient anxieties and improving recovery times in the process (https://ibn.fm/VGZDU).

However, the utilization of blue light enhancement of endoscopic procedures is a relatively new development, and most surgical centers have yet to adopt it as part of their protocols. Imagin reports in a recent company webinar that the blue light procedure helps identify 25 percent more tumors but that it is used in less than 10 percent of urological procedures, despite its recommendation by the American Urological Association.

“Clearly one of the big things with patients of bladder cancer is getting it right and getting it right the first time. And we’ve been relying on white light cystoscopy for way too long,” Dr. Ashish M. Kamat, the director of the urologic oncology fellowship at the University of Texas M.D. Anderson Cancer Center in Houston, says during an interview for the webinar (https://ibn.fm/IGuqQ).

“This year itself, in 2020, we’ve had multiple efforts, editorials and workshops, to try and improve the quality of TRBT (transurethral resection of bladder tumor), and one of the ways to do that is enhanced optical cystoscopy,” Kamat adds. “Blue light really allows us to see these tumors that the naked eye, with white light, just cannot see. It allows us to do a better diagnosis, a better resection, but unfortunately a large percentage of the market today still does not have access to blue light and hence a large percentage of patients just don’t have access to the best technology that there is to offer for resection. It’s a shame!”

One benefit of Imagin’s technology is that it “addresses the limiting factors of” current systems by making its surgical light source, video camera and data recording technology adaptable to almost any scope already on the market. The light source then displays white and blue light images side-by-side on the surgeon’s monitor without a need to toggle back and forth between one image and the other.

At the beginning of 2020, the American Cancer Society estimated about 81,400 new cases of bladder cancer would be reported during the year — the vast majority of them in men (https://ibn.fm/KpvOR). The organization anticipates that, of the more than 600,000 living patients already diagnosed and treated for bladder cancer at least once, about 17,980 of them will die  . Bladder cancer is thus the second most common malignancy of the genitourinary system after prostate adenocarcinoma (https://ibn.fm/MFVl1). It is the fourth most common cancer overall in men, according to the ACS. Bladder cancer has the highest recurrence rate of all cancers at more than 50 percent, meaning patients have significant reason to worry that their cancer will return after surgery.

While Imagin’s initial focus is on improving bladder cancer surgeries, the company intends to expand its technology for other minimally invasive surgical procedures in the future, including laparoscopic, colorectal, and thoracic that use a variety of contrast dye agents, illumination sources and physical entry points.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• The Social Media Strategies Summit First Responders is a virtual conference that will take place February 2-3, 2021, and offers a unique selection of social media expert and first responders from across the country
• Attendees of the virtual conference will receive unique opportunities for one-on-on and live Q&A sessions with presenters and others in attendance
• For over a decade, the Social Media Strategies Summit has been bringing together professionals around the same common goal of upgrading online marketing, branding, and customer relations, while providing them with the platform and expertise to move forward

Since 2009, the Social Media Strategies Summit has been producing conferences for thousands of attendees interested in upgrading their online marketing, branding, and customer relations. The upcoming 2021 virtual conference is geared toward a new set of professionals: first responders and public safety professionals.

The Social Media Strategies Summit First Responders conference is scheduled to take place online February 2-3, 2021, with a vast network of agency peers in attendance from across the country. The platform will allow attending industry experts to share experiences, learn new social media strategies, and collaborate with one another virtually.

The Social Media Strategies Summit’s virtual platform offers attendees a unique participation experience, optimizing education, learning, and networking during the First Responders’ event of 2021. The conference will have three major components:

• Exhibit Hall – The virtual exhibit hall will be much like an in-person event (only online), creating an area where attendees can interact with and learn more from the vendor sponsors of the exhibit. Attendees have the opportunity to download marketing materials, learn about new services and solutions that align with their organizational needs, and chat with sales representatives one-on-one.
• Session Rooms – The virtual session rooms allow attendees to participate in activities such as live chats with other attendees, receive answers to questions through a live Q&A after each scheduled presentation, and rewatch any portion they have missed after the conference is over.
• Networking Room – Summit opportunities include a virtual networking room where attendees get the chance to further engage with others in attendance and the featured speakers. Networking rooms have topic tables to engage further based on a set area, allow for participation in a real-time event feed, and the opportunity to chat or set up one-on-one meetings through the event’s portal.

During the two-day conference, attendees who have purchased tickets will have the opportunity to attend virtual presentations from social media giants and gain first-hand advice from other first responders. A total of 15 public sessions will be organized over the two days of the event, promising fresh perspectives and valuable insights into social media for first responders, provided by industry experts from different companies and institutions, including Facebook, UC Davis Fire Department, Fort Worth Police Department, Las Vegas Fire & Rescue, ArchiveSocial, and many more.

In addition to the main event, the conference will also feature on-demand virtual sessions:

• The One-Person Social Team: Scrappy Social Media Strategies with Big Impact – Katelyn Brower, Social Media Manager, Sterling
• Attention is Everything: Using Video to Build Brand Love and Drive Attention – Charlene Tassinari & Carli Potock, Founders, Canvas+Co
• How to Choose & Optimize the Right Social Platform for your Brand – Vanessa Williams, Director of Integrated Strategy & Promotions, and Joanie Leider, Community Manager, both from Ignite Social Media
• Copy and Creative Tips on Twitter for Higher Engagement – Sara Zaccaro, Global Paid Social Strategy Lead, Accenture

Discounted early-bird tickets for those who wish to attend the Social Media Strategies Summit First Responders virtual conference are available until January 14. After that, the general admission price will go into effect, requiring attendees to “pay at the door.”

For more information or to register, visit the event’s website at www.SocialMediaStrategiesSummit.com.